[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic renal cell carcinoma (mRCC) treatment has shifted towards targeted therapies, including sunitinib, pazopanib, bevacizumab, sorafenib, and everolimus.
• These targeted agents are increasingly replacing traditional cytokine-based therapies.
• The emergence of new therapeutic substances necessitates updated treatment guidelines.

Framework:

• An interdisciplinary expert meeting was convened to address clinical challenges arising from new mRCC therapies.
• The meeting built upon findings from a 2010 conference, with results from the 2011 meeting presented herein.
• Key discussion points included therapy selection criteria, remission assessment during antiangiogenic therapy, and optimal treatment sequencing.

Implementation:

• The presented theses offer guidance for clinicians managing mRCC patients.
• Focus is placed on practical aspects of integrating novel targeted therapies into clinical practice.
• The need for clear criteria in therapy decisions and response evaluation is highlighted.

Implications:

• Optimizing treatment selection and sequencing is crucial for improving patient outcomes in mRCC.
• Standardized methods for assessing remission under antiangiogenic agents are needed.
• These expert recommendations aim to guide the evolving landscape of mRCC treatment.